Tim Gerdeman and Do Kim discuss the current state of biotech, what brought us here, and how the rest of year may look for the group. They also review recent market-shaping events in the obesity space and progress of the Keytruda-busting PD-1/VEGF bispecifics.

On this week's episode of WTR Biotech Spotlight, Tim Gerdeman and Robert Sassoon sit down for a quick flashcast to review Robert's last three reports; Neuroscience, Alzheimer’s and Biogen IOC.

Founding CEO and President of Annovis Bio (NYSE: ANVS) Dr Maria Maccecchini joins WTR's Tim Gerdeman and Robert Sassoon in this week's WTR Biotech Spotlight episode. Annovis is a late clinical-stage drug platform company developing novel disease-modifying therapies for neurodegenerative diseases, to include targeting Alzheimer's and Parkinson's, as well as other related diseases. Dr Maccecchini discusses the company's lead drug candidate Buntanetap and its promise as a treatment that can go beyond simply slowing the rate of cognitive decline in Alzheimer's and Parkinson's patients.

CEO Mitch Steiner joins us on this week’s WTR Biotech Spotlight to talk about the next generation of drugs focusing on lean mass (muscle) preservation for obesity patients on the popular GLP-1 therapies. He reviews the recent enobosarm Phase 2b data and highlights the importance of functional clinical benefit in addition to maintaining lean mass. Listen to learn more about Veru and its obesity drug enobosarm

CEO Paul Romness and CBO Gerald Commisiong of OS Therapies join us on our WTR Biotech Spotlight podcast to talk about the OST-HER2 Phase 2b data in recurrent, liver metastatic osteosarcoma and what it could mean for patients with this aggressive cancer. We discuss the plan to approach the FDA and their confidence in a potential accelerated filing. Listen to learn more about OS Therapies and its cancer immunotherapy.

We are launching a WTR Spotlight podcast focused on biotech companies and industry. Listen to Tim Gerdeman, Vice Chair & Co-Founder and Chief Marketing Officer of Water Tower Research, and Do Kim, Senior Research Analyst, discuss what to expect and who will be joining us in future episodes.